| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Gullick WJ | |
| Bazley LA | |||
| P304 | page(s) | S17-27 | |
| P577 | publication date | 2005-07-01 | |
| P1433 | published in | Endocrine-Related Cancer | Q3054004 |
| P1476 | title | The epidermal growth factor receptor family | |
| P478 | volume | 12 Suppl 1 |
| Q34486255 | A prognostic analysis of pediatrics central nervous system small cell tumors: evaluation of EGFR family gene amplification and overexpression |
| Q36981918 | Activated epidermal growth factor receptor in ovarian cancer. |
| Q33769838 | Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors |
| Q86283685 | Activation of the EGFR/Akt/NF-κB/cyclinD1 survival signaling pathway in human cholesteatoma epithelium |
| Q36662891 | Activation of the epidermal growth factor receptor by hydrogels in artificial tears |
| Q41140262 | Aminoflavone-loaded EGFR-targeted unimolecular micelle nanoparticles exhibit anti-cancer effects in triple negative breast cancer |
| Q39195597 | Apple procyanidins affect several members of the ErbB receptor tyrosine kinase family in vitro |
| Q34023695 | Biological subtypes of breast cancer: Prognostic and therapeutic implications |
| Q34023414 | Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS |
| Q37571930 | Capilliposide from Lysimachia capillipes inhibits AKT activation and restores gefitinib sensitivity in human non-small cell lung cancer cells with acquired gefitinib resistance |
| Q36334562 | Characterization of the expression and clinical features of epidermal growth factor receptor and vascular endothelial growth factor receptor-2 in esophageal carcinoma |
| Q45210729 | Co-expression of receptors of the HER family correlates with clinical outcome in non-small cell lung cancer (NSCLC). |
| Q35742383 | Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancer |
| Q37264074 | Constitutive EGFR signaling in oligodendrocyte progenitors leads to diffuse hyperplasia in postnatal white matter |
| Q42113818 | Contrast Enhancement on Cone-Beam Breast-CT for Discrimination of Breast Cancer Immunohistochemical Subtypes |
| Q39251672 | Crosstalk between EGFR and integrin affects invasion and proliferation of gastric cancer cell line, SGC7901. |
| Q57139047 | Development of a Nanostructured Platform for Identifying HER2-Heterogeneity of Breast Cancer Cells by Surface-Enhanced Raman Scattering |
| Q39662895 | Development of a new epidermal growth factor receptor positron emission tomography imaging agent based on the 3-cyanoquinoline core: Synthesis and biological evaluation |
| Q37815607 | Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma |
| Q37260078 | EGF-receptor regulation of matrix metalloproteinases in epithelial ovarian carcinoma |
| Q39139802 | EGFR-SGLT1 interaction does not respond to EGFR modulators, but inhibition of SGLT1 sensitizes prostate cancer cells to EGFR tyrosine kinase inhibitors |
| Q42085741 | Effect of protein kinase C and Ca(2+) on p42/p44 MAPK, Pyk2, and Src activation in rat conjunctival goblet cells |
| Q54999009 | Effect of psoriasis activity and topical treatment on plasma epidermal growth factor (EGF) and its soluble receptor (sEGFR). |
| Q40145522 | Effects of silymarin on the spontaneous proliferation and cell cycle of human peripheral blood leukemia T cells |
| Q36065121 | Epidermal Growth Factor Receptor Mutation Enhances Expression of Cadherin-5 in Lung Cancer Cells |
| Q39489171 | Epidermal growth factor enhances the malignant phenotype in canine mammary carcinoma cell lines. |
| Q42443345 | Epidermal growth factor receptor activation by diesel particles is mediated by tyrosine phosphatase inhibition. |
| Q40207235 | Epidermal growth factor receptor in adult retinal neurons of rat, mouse, and human |
| Q92885375 | Epidermal growth factor receptor is a host-entry cofactor triggering hepatitis B virus internalization |
| Q37200831 | ErbB3 downregulation enhances luminal breast tumor response to antiestrogens |
| Q38101604 | Erlotinib in the first-line treatment of non-small-cell lung cancer |
| Q36672323 | Estrogen modulation of MgATPase activity of nonmuscle myosin-II-B filaments |
| Q36681198 | Estrogen regulates epithelial cell deformability by modulation of cortical actomyosin through phosphorylation of nonmuscle myosin heavy-chain II-B filaments |
| Q37446067 | Evaluation of the antitumor activity of dacomitinib in models of human bladder cancer |
| Q39011393 | Functional expression of a single-chain antibody fragment against human epidermal growth factor receptor 2 (HER2) in Escherichia coli |
| Q39565133 | Furanodienone induces cell cycle arrest and apoptosis by suppressing EGFR/HER2 signaling in HER2-overexpressing human breast cancer cells. |
| Q30009190 | GRB2 Nucleates T Cell Receptor-Mediated LAT Clusters That Control PLC-γ1 Activation and Cytokine Production. |
| Q28473274 | HER2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of alternative HER receptors in breast cancer cells |
| Q35622862 | HER2: biology, detection, and clinical implications |
| Q37044197 | HER3 signalling is regulated through a multitude of redundant mechanisms in HER2-driven tumour cells |
| Q35740066 | Inhibition of non-small cell lung cancer (NSCLC) growth by a novel small molecular inhibitor of EGFR. |
| Q34104798 | Lung injury and cancer: Mechanistic insights into ceramide and EGFR signaling under cigarette smoke |
| Q91638252 | Mechanism of Xu Li's Experiential Prescription for the Treatment of EGFR-Positive NSCLC |
| Q37112684 | Mediator of ERBB2-driven cell motility (MEMO) promotes extranuclear estrogen receptor signaling involving the growth factor receptors IGF1R and ERBB2 |
| Q38075499 | Metastatic gastric cancer treatment: a little slow but worthy progress |
| Q34560236 | Molecular mechanism of the schedule-dependent synergistic interaction in EGFR-mutant non-small cell lung cancer cell lines treated with paclitaxel and gefitinib |
| Q26750719 | Molecularly targeted therapy for the treatment of head and neck cancer: a review of the ErbB family inhibitors |
| Q54624593 | New vandetanib analogs: fused tricyclic quinazolines with antiangiogenic potential. |
| Q28730668 | Nuclear targeting of IGF-1 receptor in orbital fibroblasts from Graves' disease: apparent role of ADAM17 |
| Q33809397 | Overexpression of c-erbB2 is a negative prognostic factor in anaplastic astrocytomas |
| Q24318725 | Phosphorylation of ErbB4 on tyrosine 1056 is critical for ErbB4 coupling to inhibition of colony formation by human mammary cell lines |
| Q36245418 | Polyclonal HER2-specific antibodies induced by vaccination mediate receptor internalization and degradation in tumor cells. |
| Q46953907 | Prostatic-like acid phosphatase in human endometrial glands and its cyclic activity |
| Q52668831 | Redox regulation of epidermal growth factor receptor signaling during the development of pulmonary hypertension. |
| Q34417886 | Role of erlotinib in first-line and maintenance treatment of advanced non-small-cell lung cancer |
| Q33507260 | Roles of specific membrane lipid domains in EGF receptor activation and cell adhesion molecule stabilization in a developing olfactory system |
| Q37355121 | Sex-specific association of epidermal growth factor gene polymorphisms with acute respiratory distress syndrome. |
| Q37579650 | Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs |
| Q36648414 | Signal integration during development: mechanisms of EGFR and Notch pathway function and cross-talk |
| Q35872107 | Signal reachability facilitates characterization of probabilistic signaling networks |
| Q38302515 | Specific Grb2-mediated interactions regulate clathrin-dependent endocytosis of the cMet-tyrosine kinase |
| Q35920656 | Structural Study of the HD-PTP Bro1 Domain in a Complex with the Core Region of STAM2, a Subunit of ESCRT-0. |
| Q46370487 | Synthesis and biological evaluation of 2-styrylquinolines as antitumour agents and EGFR kinase inhibitors: molecular docking study. |
| Q49889078 | Synthesis, antitumour and antioxidant activities of novel α,β-unsaturated ketones and related heterocyclic analogues: EGFR inhibition and molecular modelling study |
| Q38851114 | Targeted Therapy in Head and Neck Cancer: An Update on Current Clinical Developments in Epidermal Growth Factor Receptor-Targeted Therapy and Immunotherapies |
| Q36326247 | Targeting cancer by binding iron: Dissecting cellular signaling pathways |
| Q33845082 | Targeting the sheddase activity of ADAM17 by an anti-ADAM17 antibody D1(A12) inhibits head and neck squamous cell carcinoma cell proliferation and motility via blockage of bradykinin induced HERs transactivation |
| Q30402360 | The Tyrosine Kinase Inhibitor Gefitinib Restricts Mycobacterium tuberculosis Growth through Increased Lysosomal Biogenesis and Modulation of Cytokine Signaling. |
| Q38384986 | The application of click chemistry in the synthesis of agents with anticancer activity |
| Q36700065 | The desmosome and pemphigus |
| Q88021269 | The dual-inhibitory effect of miR-338-5p on the multidrug resistance and cell growth of hepatocellular carcinoma |
| Q35357793 | The effect of epiregulin on epidermal growth factor receptor expression and proliferation of oral squamous cell carcinoma cell lines |
| Q37290512 | The molecular genetics of breast cancer and targeted therapy |
| Q34493341 | The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis |
| Q53584304 | The profile of the epidermal growth factor system in rat endometrium during postpartum involution period. |
| Q35657873 | The receptor tyrosine kinase ErbB3 maintains the balance between luminal and basal breast epithelium |
| Q37339233 | The role of EGFR/PI3K/Akt/cyclinD1 signaling pathway in acquired middle ear cholesteatoma |
| Q34054213 | The role of HER2 in cancer therapy and targeted drug delivery |
| Q37784574 | The role of Sp1 and Sp3 in normal and cancer cell biology |
| Q36583507 | The role of the epidermal growth factor receptor in breast cancer |
| Q38705556 | The soluble protease ADAMDEC1 released from activated platelets hydrolyzes platelet membrane pro-epidermal growth factor (EGF) to active high-molecular-weight EGF. |
| Q38891976 | The strange connection between epidermal growth factor receptor tyrosine kinase inhibitors and dapsone: from rash mitigation to the increase in anti-tumor activity |
| Q38412163 | Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics. |
| Q36230812 | Use of protein array technology to investigate receptor tyrosine kinases activated in hepatocellular carcinoma |
| Q35585670 | Using a novel microRNA delivery system to inhibit osteoclastogenesis |
| Q54658801 | [A review of epidermal growth factor receptor/HER2 inhibitors in the treatment of patients with non-small-cell lung cancer]. |
| Q40207738 | gamma-Tocotrienol inhibits ErbB3-dependent PI3K/Akt mitogenic signalling in neoplastic mammary epithelial cells |
Search more.